Norio Itokawa - Concepedia

Author

Norio Itokawa

Nippon Medical School ORCID

Also Known As

Itokawa, N., N. Itokawa, N., Itokawa, Norio Itokawa, Shintaro Ogawa

258

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Nippon Medical School Ogaki Municipal Hospital Kagawa Prefectural Central Hospital Asahi General Hospital Ehime Prefectural Central Hospital

About

Norio Itokawa is an author at Nippon Medical School specializing in medicine, hepatology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	649
2	Health Sciences	6	6	184
3	Public Health	2	2	77
4	Epidemiology	2	2	77
5	Diabetes	1	1	49

Norio Itokawa

104

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, Cancer Medicine	2019	158
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Cancer Medicine	2018	130
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima, ESMO Open	2022	124
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada, European Journal of Cancer OncologyHepatologyMedicinePathologyBevacizumab Versus Lenvatinib	2022	123
Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease Erina Kumagai, Yohei Mano, Sachiyo Yoshio, Scientific Reports	2016	105
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Liver International	2020	95
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, Oncology	2019	83
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase Daniel Q. Huang, Andrew Tran, Ming‐Lun Yeh, Hepatology	2023	83
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan Sadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, Investigational New Drugs	2019	79
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma Susumu Maruta, Sadahisa Ogasawara, Yoshihiko Ooka, Liver Cancer	2020	78

Page 1